Diabetes peripheral neuropathy is one of the chronic complications of diabetes, which is mainly manifested by peripheral nerve dysfunction, such as numbness, pain, cold and other sensory abnormalities at the end of the limbs. The treatment of diabetes peripheral neuropathy aims to alleviate symptoms, improve neurological function, control blood sugar, and prevent the further development of the disease.
The treatment of diabetes peripheral neuropathy usually includes general treatment (such as diet conditioning, exercise, etc.), drug treatment and traditional Chinese medicine acupuncture and moxibustion treatment. The treatment process should comprehensively consider the specific situation of the patient and adopt an individualized treatment plan.
Overview of Market Development
In recent years, the number of patients with diabetes has been increasing due to changes in lifestyle, bad eating habits and other factors, and the demand for prevention and treatment of neuropathy is growing. According to our research data, the global diabetic peripheral neuropathy treatment market revenue in 2024 is estimated to be $1527 million, an increase of 10.32% over 2023, and is expected to continue to increase to $2493 million by 2029. The CAGR for 2024-2029 is estimated to be 10.32%.
Segmented Market Analysis
From the perspective of drug treatment market, drugs for diabetes peripheral neuropathy mainly include pregabalin, duloxetine and capsaicin. Among them, pegabalin dominates the market with an estimated market share of 61.30% in 2024.
From the perspective of treatment facilities, hospitals dominate and are expected to have a market share of 61.48% by 2024.
Global Diabetic Peripheral Neuropathy Treatment Market Analysis
Source: www.globalmarketmonitor.com
Market Analysis of Major Regions
From a regional perspective, the global diabetic peripheral neuropathy treatment market is concentrated in North America, Europe and Asia Pacific. Among them, North America is the largest revenue market, with a revenue share of nearly 40%. From a national perspective, the US is the largest revenue generating country. Data shows that in 2024, the revenue of diabetes peripheral neuropathy treatment market in the US is estimated to be $565 million, and the revenue share is expected to reach 37.00%.
Global Diabetic Peripheral Neuropathy Treatment Market Revenue and Revenue Share by Region/Country Forecast in 2024
|
Regions/Countries
|
Market Revenue (Million USD)
|
Revenue Share
|
|
US
|
565
|
37.00%
|
|
Europe
|
461
|
30.19%
|
|
China
|
199
|
13.03%
|
|
Japan
|
49
|
3.21%
|
|
India
|
69
|
4.52%
|
|
Southeast Asia
|
46
|
3.01%
|
|
Latin America
|
35
|
2.29%
|
|
Middle East & Africa
|
43
|
2.82%
|
Source: www.globalmarketmonitor.com
For more industry information, please refer to our latest released "2023 Global Diabetic Peripheral Neuropathy Treatment Market Analysis Report, Key Competitors, Market Effect Factors, Growth, And Forecast".
Chinese